Strategic and Chemical Advances in Antibody-Drug Conjugates

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapeutics, merging monoclonal antibodies (mAbs) with cytotoxic small-molecule drugs.
• ADCs selectively deliver potent agents to cancer cells by linking antibodies to payloads via chemical linkers, enhancing the therapeutic index by sparing healthy tissues.
• Humanized and fully human IgG1 antibodies are frequently used as ADC backbones due to their stability, effector functions, and low immunogenicity.

Purpose of the Study:

• To critically review established and emerging conjugation strategies for ADCs.
• To discuss the influence of conjugation site, drug-to-antibody ratio (DAR), and linker stability on ADC pharmacokinetics, efficacy, and safety.
• To highlight current progress and future directions for next-generation ADCs.

Main Methods:

• Examination of various conjugation strategies, including lysine/cysteine-based chemistries, enzymatic tagging, glycan remodeling, non-canonical amino acid incorporation, and affinity peptide-mediated methods.
• Analysis of how conjugation site, DAR control, and linker stability impact ADC properties.
• Review of novel ADC architectures and their potential to address challenges like tumor heterogeneity and drug resistance.

Main Results:

• Advances in antibody engineering, linker chemistry, and payload innovation have led to over a dozen FDA-approved ADCs and numerous clinical trials.
• Site-specific conjugation has improved ADC homogeneity, stability, and clinical predictability.
• Novel ADC designs (bispecific, probody, immune-stimulating, protein-degrader, dual-payload) are emerging to overcome resistance and toxicity.

Conclusions:

• ADCs have demonstrated significant clinical success, with ongoing innovation driving the development of next-generation agents.
• Site-specific conjugation and novel architectures offer promising avenues for enhanced efficacy and safety in treating refractory cancers.
• Continued research integrating mechanistic insights and technological advances is crucial for optimizing ADC therapy and improving patient outcomes.